Loading...

MCRB SERES THERAPEUTICS INC Expansion Plans 8-K Filing

SRS

MCRB

SERES THERAPEUTICS INC

(MCRB)

2025 8-K

Show Summary

Summary

Financial Statements

Stockholder Approvals

Financial Results

Management Change

Board Appointment

Corporate Update

Financial Update

Stock Price Notice

Business Sale Approved

SER-155 Study Results

Financial Disclosure

Asset Purchase Agreement

Asset Purchase Agreement

Financial Results Announcement

Delisting Notice

Annual Meeting Approval

Financial Results Announcement

Appointment of CFO

Annual Meeting Announcement

Financial Results Announcement

Regulation FD Disclosure

Bylaws Amendments

Financial Results Announcement

Resignation of Director

Financial Results Announcement

Amendment to Restated Certi...

Annual Meeting of Stockholders

Financial Results Announcement

Credit Agreement and FDA Ap...

Financial Results Announcement

Appointment of Director

External Links:

Seres Therapeutics announced preliminary cash of $31 million as of December 31, 2024, and positive biomarker results from its SER-155 Phase 1b study, which may help reduce bloodstream infections in patients undergoing stem cell transplants.

AI Assistant

SERES THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.